why choose us

300×250 Ad Slot

Drug FDA Status

Showing 40 of 144 result(s) (Page 4 of 15)
Drug Name: penpulimab-kcqx

Active Ingredient: penpulimab-kcqx

Approval Date: 2025-04-23

Description: In combination with either cisplatin or carboplatin and gemcitabine, to treat adults with recurrent or metastatic non-keratinizing nasopharyngeal carcinoma (NPC), or as a single agent while on or after platinum-based chemotherapy and at least one other prior line of therapy
Drug Trials Snapshot

Drug Name: Vanrafia

Active Ingredient: atrasentan

Approval Date: 2025-04-02

Description: To reduce proteinuria in adults with primary immunoglobulin A nephropathy at risk of rapid disease progression
Drug Trials Snapshot

Drug Name: Qfitlia

Active Ingredient: fitusiran

Approval Date: 2025-03-28

Description: To prevent or reduce the frequency of bleeding episodes in hemophilia A or B
Press Release
Drug Trials Snapshot

Drug Name: Blujepa

Active Ingredient: gepotidacin

Approval Date: 2025-03-25

Description: To treat uncomplicated urinary tract infections
Drug Trials Snapshot

Drug Name: Romvimza

Active Ingredient: vimseltinib

Approval Date: 2025-02-14

Description: To treat symptomatic tenosynovial giant cell tumor for which surgical resection will potentially cause worsening functional limitation or severe morbidity
Drug Trials Snapshot

Drug Name: Gomekli

Active Ingredient: mirdametinib

Approval Date: 2025-02-11

Description: To treat neurofibromatosis type 1 who have symptomatic plexiform neurofibromas not amenable to complete resection 
Drug Trials Snapshot

Drug Name: Journavx

Active Ingredient: suzetrigine

Approval Date: 2025-01-30

Description: To treat moderate to severe acute pain
Press Release 
Drug Trials Snapshot

Drug Name: Grafapex

Active Ingredient: treosulfan

Approval Date: 2025-01-21

Description: For use in combination with fludarabine as a preparative regimen for allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia and myelodysplastic syndrome
Drug Trials Snapshot

Drug Name: Datroway

Active Ingredient: datopotamab deruxtecan-dlnk

Approval Date: 2025-01-17

Description: To treat unresectable or metastatic, HR-positive, HER2-negative breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease
Drug Trials Snapshot

Drug Name: Alhemo

Active Ingredient: concizumab-mtci

Approval Date: 2024-12-20

Description: For routine prophylaxis to prevent bleeding episodes in hemophilia A and B

300×250 Ad Slot